FDA Approves Tukysa for Advanced HER2+ BC

Options
Moderators
Moderators Member Posts: 25,912
edited April 2020 in Stage IV/Metastatic Breast Cancer, Open to All To Contribute

Have you been diagnosed with advanced-stage HER2-positive breast cancer that has been treated with at least once anti-HER2 regimen and are considering which treatments to try next? On April 17, 2020, the FDA approved Tukysa (chemical name: tucatinib) in combination with Herceptin and Xeloda to treat metastatic HER2-positive breast cancer or locally-advanced HER2-positive disease that can't be completely removed with surgery.

Read the breaking news story here, and leave your comments below.


Read more about Tukysa (chemical name: tucatinib).

· Share on FacebookShare on Twitter

Comments

Categories